Intercure Ltd is a prominent player in the global cannabis industry, focusing on the cultivation, production, and distribution of medical cannabis products
The company is dedicated to providing high-quality cannabis solutions for patients, emphasizing the therapeutic benefits of its offerings. With a commitment to innovation and research, Intercure aims to expand its market presence and improve the accessibility of medical cannabis, while also adhering to stringent regulatory standards. Through strategic partnerships and a diverse product portfolio, the company seeks to position itself as a leader in the ever-evolving cannabis market.
InterCure Ltd. (NASDAQINCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across Germany, through Cookies Corners. This agreement marks an expansion of InterCure and Cookies’ partnership footprint in Europe now covering the UK, Austria, and Germany, alongside strategic collaborations in Israel.
Some European cannabis companies are already planning initial public offerings (IPOs) on the Nasdaq, encouraged by the prospect of a less restrictive regulatory environment. The potential rescheduling of cannabis to Schedule III of the Controlled Substances Act and Germany’s recent decriminalization have ignited optimism within the sector.
InterCure Ltd. (NASDAQINCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City.
InterCure Ltd. (NASDAQINCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
InterCure Ltd. (NASDAQINCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
InterCure Ltd. (NASDAQINCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.
InterCure Ltd. (NASDAQINCR) (TASE: INCR), which is doing business as Canndoc, reported its financial and operating results on Thursday for the three and six months ended June 30, 2023,
InterCure Ltd. (NASDAQINCR) (TSX:INCR.U) (TASE:INCR) (dba Canndoc) released its financial results for the first quarter ended March 31, 2023, revealing revenue of NIS 106 million ($29 million) representing 22% growth YoY and up 1% sequenti
